Shire buys Swiss plasma collector Sanaplasma for undisclosed price

red blood cells
In a move to bolster its access to plasma, Shire snapped up Swiss source plasma collection company Sanaplasma for an undisclosed price. (Pixabay/Geralt)

In a move to bolster its access to plasma, Shire snapped up Swiss source plasma collection company Sanaplasma for an undisclosed price.

The acquisition is designed to add to the Ireland-based pharmaceutical giant’s European plasma collection network. Financial terms of the deal weren’t disclosed.

Sanaplasma, which is based in Switzerland, operates 14 plasmapheresis centers in Europe with 11 located in the Czech Republic and three in Hungary.

Your Daily Newsletter — Free

Enjoying this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. To read on the go, sign up today to get biotech news and updates delivered right to your inbox!

Plasma is a key aspect of manufacturing immunoglobulin therapies used in treatments for certain rare immunological diseases. One of Shire’s most profitable areas is immunology, which accounted for $4.4 billion of product sales for the company in 2017. That growth had been driven by a rising global demand for subcutaneous and intravenous immunoglobulin brands, the company said.

“The acquisition of Sanaplasma demonstrates Shire’s commitment to its rapidly growing and leading immunology business,” Sue Brown, a Shire vice president, said in a statement.